文献速递心脑血管急症重症综合管理与镇静镇痛

普萘洛尔与可乐定用于重型颅脑创伤后的效果:一项先导性随机临床试验

Effect of propranolol and clonidine after severe traumatic brain injury: a pilot randomized clinical trial.
PubMed 文献 · Crit Care · 2023-06-09
一句话结论在重型颅脑创伤患者中,普萘洛尔联合可乐定虽安全可行,但未改善28天无呼吸机天数,研究因无效而提前终止。

这项II期、单中心、双盲、先导性随机安慰剂对照试验纳入16-64岁、ICU入住24小时内、格拉斯哥昏迷评分≤8分且伴颅内出血的重型颅脑创伤患者,给予普萘洛尔联合可乐定或双安慰剂共7天。主要终点为28天无呼吸机天数,因预先设定的无效规则在纳入47例(安慰剂26例、治疗21例)后终止。治疗组与对照组无呼吸机天数无显著差异[0.3天,95%CI(-5.4,5.8),p=1.0];除交感神经过度活跃相关特征改善(临床特征量表平均差异1.7分,CI(0.4,2.9),p=0.012)外,次要终点无组间差异。作者认为,鉴于此类药物在颅脑创伤救治中广泛使用,需开展多中心研究以明确肾上腺素能阻滞是否有治疗获益。

要点

  • 研究因预先设定的无效规则在纳入47例(安慰剂26例、治疗21例)后提前终止,主要终点无呼吸机天数无显著差异[0.3天,95%CI(-5.4,5.8),p=1.0]。
  • 治疗组无患者发生心律失常、心肌梗死或心脏骤停,剂量依从性99%,盲法完整,未使用开放标签药物。
  • 除交感神经过度活跃相关特征改善(临床特征量表平均差异1.7分,CI(0.4,2.9),p=0.012)外,次要终点无组间差异。
  • 作者认为,鉴于此类药物在颅脑创伤救治中广泛使用,需开展多中心研究以明确肾上腺素能阻滞是否有治疗获益。

适用人群与场景

  • 年龄16-64岁、ICU入住24小时内、重型颅脑创伤(颅内出血且格拉斯哥昏迷评分≤8分)的患者。

诊断标准与关键阈值

  • 重型颅脑创伤定义:颅内出血且格拉斯哥昏迷评分≤8分。

处置流程与药物剂量

  • 患者接受普萘洛尔联合可乐定或双安慰剂治疗7天。

研究设计与关键结果

  • II期、单中心、双盲、先导性随机安慰剂对照试验,纳入47例(安慰剂26例、治疗21例),因预先设定的无效规则提前终止。
  • 剂量依从性99%,盲法完整,未使用开放标签药物;治疗组无患者发生心律失常、心肌梗死或心脏骤停。
  • 主要终点28天无呼吸机天数无显著差异[0.3天,95%CI(-5.4,5.8),p=1.0]。
  • 除交感神经过度活跃相关特征改善(临床特征量表平均差异1.7分,CI(0.4,2.9),p=0.012)外,次要终点(儿茶酚胺水平、住院时间、死亡率、长期功能状态)无组间差异。

证据类型、等级与局限

  • 证据类型:II期、单中心、双盲、先导性随机安慰剂对照试验。
  • 局限:研究因无效而提前终止,样本量47例。

对床旁实践的改变

  • 作者认为,鉴于普萘洛尔与可乐定在颅脑创伤救治中广泛使用,需开展多中心研究以明确肾上腺素能阻滞是否有治疗获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the safety, feasibility, and efficacy of combined adrenergic blockade with propranolol and clonidine in patients with severe traumatic brain injury (TBI).

BACKGROUND: Administration of adrenergic blockade after severe TBI is common. To date, no prospective trial has rigorously evaluated this common therapy for benefit.

METHODS: This phase II, single-center, double-blinded, pilot randomized placebo-controlled trial included patients aged 16-64 years with severe TBI (intracranial hemorrhage and Glasgow Coma Scale score ≤ 8) within 24 h of ICU admission. Patients received propranolol and clonidine or double placebo for 7 days. The primary outcome was ventilator-free days (VFDs) at 28 days. Secondary outcomes included catecholamine levels, hospital length of stay, mortality, and long-term functional status. A planned futility assessment was performed mid-study.

RESULTS: Dose compliance was 99%, blinding was intact, and no open-label agents were used. No treatment patient experienced dysrhythmia, myocardial infarction, or cardiac arrest. The study was stopped for futility after enrolling 47 patients (26 placebo, 21 treatment), per a priori stopping rules. There was no significant difference in VFDs between treatment and control groups [0.3 days, 95% CI (- 5.4, 5.8), p = 1.0]. Other than improvement of features related to sympathetic hyperactivity (mean difference in Clinical Features Scale (CFS) 1.7 points, CI (0.4, 2.9), p = 0.012), there were no between-group differences in the secondary outcomes.

CONCLUSION: Despite the safety and feasibility of adrenergic blockade with propranolol and clonidine after severe TBI, the intervention did not alter the VFD outcome. Given the widespread use of these agents in TBI care, a multi-center investigation is warranted to determine whether adrenergic blockade is of therapeutic benefit in patients with severe TBI. Trial Registration Number NCT01322048.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Nordness MF, Maiga AW, Wilson LD, et al. Effect of propranolol and clonidine after severe traumatic brain injury: a pilot randomized clinical trial. Crit Care. 2023. PMID: 37296432. doi:10.1186/s13054-023-04479-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。